SME Times is powered by   
Search News
Just in:   • NDA show of strength: Nitish Kumar takes oath as Bihar CM for 10th time, PM Modi attends ceremony   • S. Korea to raise anti-dumping tariffs for 2 Chinese PET film companies  • Govt reviews RBI's proposal on opening foreign bank branches, Indian banks’ global expansion  • Sensex, Nifty end near record highs as financials lead rally  • Renewable energy share in India’s power mix likely to cross 35 pc by 2030 
Last updated: 13 Oct, 2021  

Vaccine.Thmb.jpg Hindustan Syringes to expand at an outlay of Rs 150 cr

Vaccine.jpg
   Top Stories
» Sensex, Nifty end near record highs as financials lead rally
» 26 e-commerce platforms declare compliance with self-audit to eliminate dark patterns: Govt
» Gold edges lower on stronger dollar, Fed minutes weigh on rate-cut hopes
» Financial inclusion, digital transformation are India’s big success stories: DFS Secretary
» Goyal to visit Israel for high-level trade talks, proposed FTA review on agenda
SME Times News Bureau | 13 Oct, 2021
Medical syringe major Hindustan Syringes and Medical Devices Ltd (HMD) is in the process of expanding its cannulas (needle points) and needle capillary tubing production capacity, said a top company official.

"Our capital expenditure last year was Rs 100 crore and this year, it will be over Rs 50 crore. The total capex will be Rs 150 crore on syringes and on the backward integration," Managing Director Rajiv Nath told IANS.

He said a new 1.5 lakh square feet factory within the existing 11 acre complex at Faridabad (Haryana) will be commissioned by January 2022 to increase capacity from four billion cannulas per annum to six billion per annum.

The capex will be funded internally, Nath added.

On October 11, the company achieved a milestone of supplying 500 million 0.5 ml auto disable (AD) syringes to the government to help vaccinate over 685 million people till date to support the massive vaccination campaign to eradicate Covid-19.

The next lot of 16.3 million syringes has been inspected and is ready to dispatch.

According to Nath, the company is on track to produce and supply outstanding orders of 310 million 0.5 ml Kojak AD syringes by 2022 beginning, hopefully by January end.

He requested the Central government to place orders for syringes with the manufacturers in India well in advance so that the latter could ramp up supplies or allocate supplies for the government.

Nath said with the Central government planning to resume export of surplus Covid-19 vaccines in the fourth quarter of 2021 in order to fulfill the commitment of India towards COVAX, HMD is confident that India will also be in a position to export some syringes as part of 'Vaccine & Syringe Maitri'.
 
Print the Page
Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹88.70
₹87
UK Pound
₹119.90
₹116
Euro
₹104.25
₹100.65
Japanese Yen ₹59.20 ₹57.30
As on 30 Oct, 2025
  Daily Poll
Who do you think will benefit more from the India - UK FTA in the long run?
 Indian businesses & consumers.
 UK businesses & consumers.
 Both will gain equally.
 The impact will be negligible for both.
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter